Angiotech Pharmaceuticals, Inc. ("Angiotech"), a global specialty pharmaceutical and medical device company, reported that its corporate partner, Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to market its TAXUS(R) Express(2)(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System.

The TAXUS Express Atom Stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels. It is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter. BSC plans to launch the product immediately.

"The TAXUS Express Atom Stent will provide better options for U.S. patients with coronary artery disease in small vessels," said Gregg Stone, M.D., Chairman of the Cardiovascular Research Foundation and Professor of Medicine at Columbia University Medical Center, and Principal Investigator of the TAXUS IV and V clinical trials.

Currently the leading drug-eluting stents worldwide, TAXUS Stent Systems have been evaluated by the industry's most extensive randomized, controlled clinical trial program, as well as studied in more than 35,000 real-world patients enrolled in post-approval registries. To date, approximately 4.6 million TAXUS Stents have been implanted worldwide.